LABFF — Laboratorios Farmaceuticos Rovi, S.A./ADR

OTC · Unknown · Unknown · CIK 2029970 ·
Last close
Market Cap
52W High
52W Low
ADV30
Next earnings
2026-07-23
Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express; catheter care under the Fibrilin brand; and Sodium Heparin Rovi. In addition, the company offers contract-manufacturing services comprising compounding, sterile filling and terminal sterilisation, inspection, installation of safety devices, labelling, packaging, serialisation and aggregation, for different injectable pharmaceutical forms, such as prefilled syringes, vials and cartridges, as well as manufacturing and packaging services for solid products. Further, it offers low-molecular-weight heparin, Okedi, and Rolcya; and develops Letrozole SIE and Risperidone QUAR. Its products are used for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. The company was incorporated in 1946 and is headquartered in Pozuelo de Alarcón, Spain. Laboratorios Farmaceúticos Rovi, S.A. operates as a subsidiary of Norbel Inversiones, S.L.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026
Sep 2025 210,473,000 147,813,000 76,306,000 58,029,000 922,069,000 49,250,000 289,268,000
Jun 2025 159,698,000 105,285,000 27,851,000 21,635,000 869,605,000 46,114,000 294,890,000
Mar 2025 154,892,000 90,398,000 23,096,000 18,101,000 813,963,000 29,306,000 214,495,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$174,519,000
Investing CF
$-88,687,000
Financing CF
$-56,200,000
CapEx
$-66,852,000
Dividends Paid
$0
Buybacks
$-63,804,000
EPS Diluted TTM
$2.35
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$535,382,000
Inventory
$314,785,000
Receivables
ST Investments
$1,507,000
EBIT TTM
$250,735,000
Pretax Income TTM
$246,870,000
Interest Exp TTM
$3,865,000
Analysts

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2024 763,749,000 179,545,000 136,881,000 832,022,000 250,482,000 138,278,000
Dec 2023 829,509,000 220,254,000 170,335,000 799,884,000 256,390,000 113,247,000
Dec 2022 817,698,000 255,850,000 199,669,000 878,703,000 357,324,000 237,602,000
Dec 2021 648,677,000 181,487,000 153,077,000 732,676,000 261,700,000 149,441,000

Peers — same industry

TickerNameMarket CapLastDaily %
SPY SPDR S&P 500 ETF TRUST $688.88B $750.59
KLAC KLA CORP $262.74B $2011.39
IBM INTERNATIONAL BUSINESS MACHINES CORP $235.62B $250.69
KXIAY Kioxia Holdings Corporation/ADR $231.81B $42.45
SMEGF Siemens Energy AG/ADR $180.38B $212.00

News headlines (Yahoo Finance, 1h cache)

Global Market Highlights 3 Stocks That May Be Trading Below Fair Value Estimates
2026-05-26 09:37 · Yahoo
Laboratorios Farmaceuticos Rovi SA (WBO:ROVI) Q1 2026 Earnings Call Highlights: Navigating ...
2026-05-07 22:31 · Yahoo
Laboratorios Farmaceuticos Rovi SA (STU:41L) Q4 2025 Earnings Call Highlights: Strategic Growth ...
2026-02-28 01:00 · Yahoo
3 European Stocks Estimated To Be Trading At Discounts Of Up To 46%
2026-02-11 05:38 · Yahoo
Uncovering 3 European Stocks That May Be Priced Below Intrinsic Value Estimates
2026-01-13 05:38 · Yahoo
December 2025 European Stocks That May Be Trading Below Fair Value
2025-12-15 05:37 · Yahoo
Global Value Stocks Priced Below Estimated Worth In November 2025
2025-11-14 09:37 · Yahoo
European Market Picks: 3 Stocks That May Be Trading Below Their Estimated Value
2025-10-16 05:37 · Yahoo
September 2025's European Stocks Estimated To Be Trading Below Fair Value
2025-09-11 10:38 · Yahoo
3 European Stocks Estimated To Be Trading At Discounts Up To 49.1%
2025-08-13 10:37 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.